US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
pharma · Epilepsy · Allergic Reaction · AQST
Aquestive Therapeutics
Aquestive Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Vancouver, CA HQ
2009 Founded
75 Employees
Public company Type
AQST · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, CA
- Founded
- 2009
- Employees
- 75
- Programs
- 9
- Drugs
- 9
- Patents
- 17
Aquestive Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aquestive Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Iron.
- Target
- Iron
- Mechanism
- Iron chelating agent
-
Development asset linked to Aquestive Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Aquestive Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to Aquestive Therapeutics in public FDA and regional records.
-
Development asset linked to Aquestive Therapeutics in public FDA and regional records.
-
riluzole
Nervous system (N07)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker